RXi Pharmaceuticals Corporation - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

RXi Pharmaceuticals Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'RXi Pharmaceuticals Corporation - Product Pipeline Review - 2014', provides an overview of the RXi Pharmaceuticals Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RXi Pharmaceuticals Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of RXi Pharmaceuticals Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of RXi Pharmaceuticals Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the RXi Pharmaceuticals Corporation's pipeline products

Reasons to buy

- Evaluate RXi Pharmaceuticals Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of RXi Pharmaceuticals Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the RXi Pharmaceuticals Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of RXi Pharmaceuticals Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of RXi Pharmaceuticals Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of RXi Pharmaceuticals Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
RXi Pharmaceuticals Corporation Snapshot 6
RXi Pharmaceuticals Corporation Overview 6
Key Information 6
Key Facts 6
RXi Pharmaceuticals Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
RXi Pharmaceuticals Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
RXi Pharmaceuticals Corporation - Pipeline Products Glance 14
RXi Pharmaceuticals Corporation - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
RXi Pharmaceuticals Corporation - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
RXi Pharmaceuticals Corporation - Drug Profiles 18
RXI-109 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RNAi Oligonucleotide to Inhibit CTGF for PVR 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RNAi Oligonucleotide for Retinoblastoma 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RXI-209 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
bevasiranib sodium 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MMP-26051 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MMP-26052 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RNAi Oligonucleotide for Undisclosed Indication 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RNAi Oligonucleotide to Inhibit Angiopoietin-2 for Retinal Disease and Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RNAi Oligonucleotide to Inhibit SOD-1 for ALS 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RNAi Oligonucleotide to Inhibit VEGF for Macular Degeneration 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RNAi Oligonucleotides to Inhibit Complement C3 for Undisclosed Indication 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RNAi Oligonucleotides to Inhibit TNF-alpha for Autoimmune Disorders 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TRY-26071 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TRY-26077 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RXi Pharmaceuticals Corporation - Pipeline Analysis 38
RXi Pharmaceuticals Corporation - Pipeline Products by Target 38
RXi Pharmaceuticals Corporation - Pipeline Products by Route of Administration 39
RXi Pharmaceuticals Corporation - Pipeline Products by Molecule Type 40
RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action 41
RXi Pharmaceuticals Corporation - Recent Pipeline Updates 42
RXi Pharmaceuticals Corporation - Dormant Projects 47
RXi Pharmaceuticals Corporation - Discontinued Pipeline Products 48
Discontinued Pipeline Product Profiles 48
bevasiranib sodium 48
RXi Pharmaceuticals Corporation - Locations And Subsidiaries 49
Head Office 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
RXi Pharmaceuticals Corporation, Key Information 6
RXi Pharmaceuticals Corporation, Key Facts 6
RXi Pharmaceuticals Corporation - Pipeline by Indication, 2014 9
RXi Pharmaceuticals Corporation - Pipeline by Stage of Development, 2014 10
RXi Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2014 11
RXi Pharmaceuticals Corporation - Partnered Products in Pipeline, 2014 12
RXi Pharmaceuticals Corporation - Partnered Products/ Combination Treatment Modalities, 2014 13
RXi Pharmaceuticals Corporation - Phase II, 2014 14
RXi Pharmaceuticals Corporation - IND/CTA Filed, 2014 15
RXi Pharmaceuticals Corporation - Preclinical, 2014 16
RXi Pharmaceuticals Corporation - Discovery, 2014 17
RXi Pharmaceuticals Corporation - Pipeline Products by Target, 2014 38
RXi Pharmaceuticals Corporation - Pipeline by Route of Administration, 2014 39
RXi Pharmaceuticals Corporation - Pipeline by Molecule Type, 2014 40
RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action, 2014 41
RXi Pharmaceuticals Corporation - Recent Pipeline Updates, 2014 42
RXi Pharmaceuticals Corporation - Dormant Developmental Projects,2014 47
RXi Pharmaceuticals Corporation - Discontinued Pipeline Products, 2014 48